Pancreatic cancer screening is effective in individuals at risk with predisposing germline gene variants, but not in gene variant‐negative familial pancreatic cancer families

Author:

Maurer Elisabeth1ORCID,Lehman Bettina1,Matthäi Elvira1,Denzer Ulrike2,Figiel Jens3,Jesinghaus Moritz4,Slater Emily P.1,Stefenelli Ulrich5,Gress Thomas M.2,Bartsch Detlef K.1

Affiliation:

1. Department of Visceral‐ Thoracic‐ and Vascular Surgery Philipps University Marburg Marburg Germany

2. Department of Gastroenterology Endocrinology Metabolism and Infectiology Philipps University Marburg Marburg Germany

3. Department of Diagnostic and Interventional Radiology Philipps University Marburg Marburg Germany

4. Institute of Pathology Philipps University Marburg Marburg Germany

5. Data and Statistics Dr. Ulrich Stefenelli Würzburg Germany

Abstract

AbstractObjectiveTo evaluate the diagnostic yield of pancreatic cancer screening in individuals at risk (IAR) from familial pancreatic cancer (FPC) families with respect to the presence or absence of pathogenic germline variants predisposing to pancreatic adenocarcinoma (PDAC).DesignIn a 20 years period, IAR from FPC families were enrolled in a prospective screening program of the national case collection for FPC of Germany, including magnet resonance imaging (MRI) and endoscopic ultrasound (EUS). The diagnostic yield was analyzed regarding significant pancreatic lesions such as PDAC, high‐grade pancreatic‐intraepithelial‐neoplasia (PanIN3) and intraductal‐papillary‐mucinous‐neoplasia (IPMN) with high‐grade dysplasia. Screening results were compared between carriers of pathogenic variants and variant‐negative IAR.Results337 IAR, including 74 (22%) variant‐carriers and 263 IAR of variant‐negative FPC families (mean age 49; standard deviation [SD] + 8.9) were followed 64 (SD + 55) months. IAR underwent 5.1 (SD + 3.9) screening visits with 1733 MRI (5.1,SD + 3.9 per IAR) and 728 EUS (2.2,SD + 1.7 per IAR). In 12 (4%) cases, significant pancreatic lesions were detected, including 4 PDAC, 3 PanIN3 and 5 high‐grade IPMN. Three of 4 IAR with PDAC died after a mean of 27 months postoperatively, and one IAR is alive without evidence of disease after 31 months. The diagnostic yield for significant lesions was 13.5% (10/74) for variant carriers compared to 0.8% (2/263) for IAR of variant‐negative FPC families (p < 0.001). Logistic regression analysis revealed that a negative variant status was almost always accompanied by the absence of a significant lesion over time with a negative predictive value of 99.2% (95% CI 97.3%–99.9%).ConclusionThe diagnostic yield seems to justify PDAC screening in IAR of FPC‐families with pathogenic germline variants in PDAC predisposing genes, not in IAR of variant‐negative families.

Funder

Deutsche Krebshilfe

Publisher

Wiley

Reference53 articles.

1. ZfKD.Krebsarten.2019.https://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/krebsarten_node.html

2. Screening for Pancreatic Cancer

3. Screening for Pancreatic Cancer

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3